PeptideGlobal

Wegovy pill Australia launch puts a peptide tablet on private scripts ahead of Foundayo

GPs can prescribe Novo Nordisk's oral semaglutide privately from 20 November at about 260 to 395 Australian dollars a month. Lilly's Foundayo follows within days, and neither tablet nor the Wegovy injection is on the PBS.

Illustration for the story: Wegovy pill Australia launch puts a peptide tablet on private scripts ahead of Foundayo

Illustration by Peptide Global, not a picture of the place in the story.

The short of itNovo Nordisk's Wegovy pill became available on private prescription in Australia from 20 November, the first oral GLP-1 for weight management on Australian shelves, with no PBS subsidy.

Australia now has a semaglutide tablet for weight loss on pharmacy shelves. The Wegovy pill Australia launch began on 20 November, when GPs could start writing private prescriptions for Novo Nordisk's daily tablet, the RACGP news service newsGP reported. It is the first oral GLP 1 approved for weight management to reach Australian patients, just ahead of Eli Lilly's Foundayo. Neither tablet is on the Pharmaceutical Benefits Scheme, so patients pay the full private price, and the injectable Wegovy is still waiting for a subsidy too.

What launched and who can get it

The Therapeutic Goods Administration approved the tablet on 3 November in four strengths, with the same uses as the injection, according to an earlier newsGP approval story. It is indicated, alongside diet and exercise, for chronic weight management in adults with a body mass index of 30 or more, or 27 or more with at least one weight related condition. It is also approved to lower the risk of major heart events in adults with established cardiovascular disease and a BMI of at least 27 who do not have diabetes. Patients start on the lowest strength and move up step by step under the product information. The tablet must be taken on an empty stomach with only a small sip of water, and people wait at least half an hour before eating, drinking or taking other medicines.

Those rules matter for a peptide given by mouth. Semaglutide is a peptide that digestive enzymes would normally break down, so the tablet relies on strict timing to get enough of the drug absorbed. GPs quoted by newsGP said counselling on how to take it is a key part of the visit, along with a talk about cost and long term plans, since weight often returns when treatment stops. Novo Nordisk's Oceania senior director of medical and regulatory affairs, Dr Ana Svensson, said "people living with obesity should have options that address the barriers of starting treatment". For patients who avoid needles, a tablet removes one such barrier, though the daily routine adds another.

Wegovy pill Australia prices and the PBS gap

Price is the main hurdle. newsGP listed private prices of about 260 Australian dollars a month for the lowest strength, rising to 270 and 280 for the middle strengths and 395 for the top maintenance strength, with the final amount set by each pharmacy and the services it adds. Lilly has put recommended prices for Foundayo at 250 dollars a pack for its three smaller strengths and 370 for the two higher ones. Neither oral drug has been recommended for subsidy by the Pharmaceutical Benefits Advisory Committee. The injectable Wegovy received such a recommendation almost a year ago, but it is still not listed, and newsGP said talks with the government are continuing.

Dr Mark Mellor, chair of the RACGP obesity management interest group, said "we still don't have PBS funding for these treatments" and asked the government to look at options.

The result is a two tier market in which only people who can pay a few hundred dollars a month get any of these medicines. Dr Mark Mellor, chair of the RACGP obesity management interest group, said "we still don't have PBS funding for these treatments" and asked the government to look at options. RACGP President Dr Michael Wright said at approval that the tablet was "a step forward", adding that "obviously there are still problems around the high cost of medication." For readers outside Australia, the setup is common across the region; in many markets, oral and injectable GLP 1 drugs reach private patients long before a public payer decides whether to cover them.

ItemWegovy pillFoundayo
MakerNovo NordiskEli Lilly
Active ingredientSemaglutide, a peptideOrforglipron, a small molecule
TGA statusApproved 3 November 2026On the register, confirmed 17 November 2026
AvailablePrivate prescription from 20 November 2026Expected within days of 17 November
Private price rangeAbout 260 to 395 dollarsAbout 250 to 370 dollars
PBS listingNoneNone

Peptide tablet against small molecule

The launch sets up a direct contest between two ways of making a GLP 1 pill. Lilly's Foundayo, covered in Peptide Global's Asia Pacific desk earlier this week, is a small molecule, not a peptide, so it does not need the fasting routine. RACGP President Dr Michael Wright told newsGP that it is better absorbed by mouth for that reason. GPs, however, noted that Foundayo carries a significant risk of interactions with other medicines. The Wegovy pill has the longer record behind it. Novo said the tablet launched in the United States on 5 January and passed three million prescriptions there in just over five months, most of them for people new to GLP 1 therapy.

For doctors, the choice will turn on habits, other medicines and price. Dr Terri-Lynne South, immediate past chair of the RACGP obesity interest group, called the tablet "another tool in the GP toolbox for obesity management" and said "patient selection doesn't change". The TGA has warned against combining semaglutide products or using them with other GLP 1 receptor agonists, a point that matters now that injections and tablets sit side by side in the same pharmacies. Supply is the other unknown. Neither company has given stock figures in the reports reviewed here, and shortages of injectable semaglutide in past years show how quickly demand can outrun stock in Australia.

What to watch after the Wegovy pill Australia launch

Three things will shape the next months. The first is the subsidy question. A PBS listing for injectable Wegovy, which has been recommended but not agreed, would change the price comparison overnight, and any later application for the tablets would follow that path. The second is uptake. Pharmacy dispensing data and company reports will show whether private patients choose a daily tablet over a weekly pen at similar prices. The third is how Lilly prices and supplies Foundayo once it is widely stocked. Readers can follow approvals, launches and price moves across countries on our world atlas, where Australia now has two oral GLP 1 entries.

There are limits to what is known. Neither company has published Australian sales figures, and the prices quoted are recommended or indicative amounts that can vary between pharmacies. The reports reviewed for this story give no Australian trial data, no stock figures and no estimate of how many people may start the tablet in its first months. GPs stress that the medicine is for people who meet the approved criteria and that cost conversations should come before the first script. For now, the launch adds choice for those who can pay and leaves the public funding question where it was, with doctors' groups pressing Canberra to act.

Conclusion

The Wegovy pill Australia launch gives GPs a first oral semaglutide option for weight management from 20 November, on private prescription only at about 260 to 395 dollars a month. Lilly's cheaper small molecule Foundayo follows within days. With no PBS listing for either tablet or for injectable Wegovy, cost remains the main barrier for patients.

Why it matters in Australia

Australia has no public subsidy for any GLP-1 weight loss drug, so the tablet and Lilly's cheaper Foundayo compete for private patients paying a few hundred dollars a month while the injectable Wegovy still waits for its PBS listing.

What to watch

Whether the government agrees a PBS listing for injectable Wegovy, how Foundayo is priced and supplied once stocked, and dispensing data on tablet uptake.

Sources

  1. newsGP: First weight-loss pill now available to prescribe
  2. newsGP: TGA approves Wegovy weight-loss pill
  3. newsGP: New oral GLP-1 to hit Australian shelves within days

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.